Back to School: How biopharma can reboot drug development. Access exclusive analysis here

'Strike 2' for breakthrough panel

WASHINGTON - Rep. John J. Moakley, D-Mass., chairman of the House Rules Committee that will reconcile the various health care reform bills, last week sent to President Clinton a letter strongly opposing the Breakthrough Drug Advisory Council provision of the Health Security Act.

Specifically, Moakley warned that the breakthrough committee would have several "unintended adverse

Read the full 542 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers